IL292798A - Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses - Google Patents

Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses

Info

Publication number
IL292798A
IL292798A IL292798A IL29279822A IL292798A IL 292798 A IL292798 A IL 292798A IL 292798 A IL292798 A IL 292798A IL 29279822 A IL29279822 A IL 29279822A IL 292798 A IL292798 A IL 292798A
Authority
IL
Israel
Prior art keywords
seq
amino acid
antibody
acid sequence
activatable antibody
Prior art date
Application number
IL292798A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of IL292798A publication Critical patent/IL292798A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL292798A 2015-05-04 2016-05-04 Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses IL292798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156835P 2015-05-04 2015-05-04
US201562220805P 2015-09-18 2015-09-18
PCT/US2016/030785 WO2016179285A1 (en) 2015-05-04 2016-05-04 Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
IL292798A true IL292798A (en) 2022-07-01

Family

ID=55967468

Family Applications (2)

Application Number Title Priority Date Filing Date
IL292798A IL292798A (en) 2015-05-04 2016-05-04 Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
IL255414A IL255414B (en) 2015-05-04 2017-11-02 Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL255414A IL255414B (en) 2015-05-04 2017-11-02 Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses

Country Status (20)

Country Link
US (3) US10745481B2 (enExample)
EP (2) EP3292150B1 (enExample)
JP (2) JP7028648B2 (enExample)
KR (1) KR20180010203A (enExample)
CN (2) CN107849133B (enExample)
AU (1) AU2016257929B2 (enExample)
BR (1) BR112017023872A2 (enExample)
CA (1) CA2984948A1 (enExample)
DK (1) DK3292150T3 (enExample)
EA (1) EA201792414A1 (enExample)
ES (1) ES2796698T3 (enExample)
HR (1) HRP20200721T1 (enExample)
HU (1) HUE049866T2 (enExample)
IL (2) IL292798A (enExample)
MX (2) MX388350B (enExample)
PL (1) PL3292150T3 (enExample)
PT (1) PT3292150T (enExample)
RS (1) RS60222B1 (enExample)
SG (2) SG10201913767VA (enExample)
WO (1) WO2016179285A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
EP4067383A1 (en) * 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
EP4176896B1 (en) * 2014-01-31 2025-10-08 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
IL300408B2 (en) * 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
ES2990113T3 (es) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Conjugados de adyuvantes de anticuerpos
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
BR112019008265A2 (pt) 2016-11-28 2019-07-09 Chugai Pharmaceutical Co Ltd molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
NZ753324A (en) 2016-12-09 2022-02-25 Seagen Inc Bivalent antibodies masked by coiled coils
KR20200027971A (ko) * 2017-07-14 2020-03-13 싸이톰스 테라퓨틱스, 인크. 항-cd166 항체 및 이의 용도
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP2020531430A (ja) 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗体を標的とする抗ｃｔｌａ４プロボディ療法
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
US20190117789A1 (en) 2017-08-30 2019-04-25 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
EP3679068A2 (en) * 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
KR20240170847A (ko) 2017-09-08 2024-12-04 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
FI3794024T3 (fi) 2018-05-14 2023-08-10 Werewolf Therapeutics Inc Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JPWO2019230868A1 (ja) 2018-05-30 2021-06-24 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
JP2022512920A (ja) * 2018-11-02 2022-02-07 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗ｃｄ１６６抗体およびその使用方法
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP7695698B2 (ja) * 2019-01-14 2025-06-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞内部移行をモジュレートするための組成物および方法
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
US20220233705A1 (en) * 2019-02-26 2022-07-28 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
CN114390938B (zh) 2019-03-05 2025-03-21 武田药品工业有限公司 受约束的条件性活化的结合蛋白
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
KR102212149B1 (ko) * 2019-03-28 2021-02-04 부산대학교 산학협력단 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도
PT3958977T (pt) 2019-04-26 2023-12-15 Immunogen Inc Derivados de camptotecina
AU2020275877B2 (en) 2019-05-14 2025-07-24 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
US20220226514A1 (en) * 2019-05-17 2022-07-21 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
JP2022548310A (ja) * 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
CA3174665A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4243851A4 (en) * 2020-11-16 2025-08-20 Cleveland Clinic Found ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL AND B-CELL MEDIATED DISORDERS, AND T-CELL AND B-CELL CANCERS
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
IL312143A (en) 2021-10-15 2024-06-01 Amgen Inc An activatable polypeptide complex
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250011422A1 (en) * 2021-11-12 2025-01-09 University Of Florida Research Foundation, Incorporated Siglec-6 antibodies, derivative compounds and related uses
CN114621348B (zh) * 2022-01-24 2023-09-22 深圳市乐土生物医药有限公司 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
CN119301151A (zh) 2022-03-25 2025-01-10 西托姆克斯治疗公司 可激活双锚定掩蔽分子和其使用方法
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
CN119343374A (zh) 2022-05-16 2025-01-21 拜奥迪斯私人有限公司 新的掩蔽抗体
AR129896A1 (es) 2022-07-12 2024-10-09 Cytomx Therapeutics Inc INMUNOCONJUGADOS DE EpCAM Y USOS DE ESTOS
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
TW202423953A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
WO2024030843A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
AR130078A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
EP4565260A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024216146A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025047993A1 (en) * 2023-08-28 2025-03-06 Pharosgen Co., Ltd. Anti-doppel antibody drug conjugates
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU2001293995B2 (en) 2000-10-09 2005-10-13 Cytomx Therapeutics, Inc. Therapeutic antibodies
CN1662254A (zh) 2002-05-03 2005-08-31 雷文生物技术公司 Alcam和alcam调制剂
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
AR048912A1 (es) 2003-12-22 2006-06-14 Glaxo Group Ltd Inmunoglobulinas anti-nogo
JP4487051B2 (ja) 2005-08-29 2010-06-23 独立行政法人科学技術振興機構 ダチョウを用いた抗体、及びその作製方法
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
JP5612247B2 (ja) 2005-11-29 2014-10-22 独立行政法人科学技術振興機構 Ｃｄ１６６に対するモノクローナル抗体およびその産生方法
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
JP2009055899A (ja) 2007-08-07 2009-03-19 Igaku Seibutsugaku Kenkyusho:Kk Ａｄｃｃ活性を増強させた抗体及びその製造方法
JP6035009B2 (ja) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
WO2009039192A2 (en) 2007-09-17 2009-03-26 The Regents Of The University Of Californina Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
CN104193824A (zh) 2008-02-20 2014-12-10 G2炎症私人有限公司 人源化抗-C5aR抗体
WO2009134952A2 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
EP2388320B1 (en) 2008-12-22 2017-02-15 Chugai Seiyaku Kabushiki Kaisha Anti-hs6st2 antibodies and uses thereof
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
CN106349254A (zh) 2010-11-03 2017-01-25 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
AU2012253373A1 (en) * 2011-05-11 2013-11-28 Nanovalent Pharmaceuticals, Inc. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
HUE037021T2 (hu) * 2012-02-24 2018-08-28 Abbvie Stemcentrx Llc DLL3- modulátorok és eljárások alkalmazásukra
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
MX2015007846A (es) 2012-12-19 2016-04-28 Amplimmune Inc Anticuerpos anti-b7-h4 humana y sus usos.
AU2014204015A1 (en) 2013-01-04 2015-07-09 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
EP4067383A1 (en) * 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
WO2017015227A1 (en) 2015-07-17 2017-01-26 The Trustees Of Columbia University In The City Of New York Methods of treating cd166-expressing cancer
JP7534070B2 (ja) 2015-11-04 2024-08-14 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
JP6183523B2 (ja) 2016-09-14 2017-08-23 株式会社アンセイ 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11376332B2 (en) 2016-10-15 2022-07-05 Baylor College Of Medicine Platform for enhanced targeted delivery
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
KR20200027971A (ko) 2017-07-14 2020-03-13 싸이톰스 테라퓨틱스, 인크. 항-cd166 항체 및 이의 용도
US20190117789A1 (en) 2017-08-30 2019-04-25 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
JP2022512920A (ja) 2018-11-02 2022-02-07 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗ｃｄ１６６抗体およびその使用方法
US20220233705A1 (en) 2019-02-26 2022-07-28 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies

Also Published As

Publication number Publication date
PL3292150T3 (pl) 2020-07-13
IL255414A0 (en) 2017-12-31
SG10202110908WA (en) 2021-11-29
IL255414B (en) 2022-06-01
US11753466B2 (en) 2023-09-12
JP2022065115A (ja) 2022-04-26
EP3292150B1 (en) 2020-02-05
JP7028648B2 (ja) 2022-03-02
AU2016257929A1 (en) 2017-11-30
EP3292150A1 (en) 2018-03-14
BR112017023872A2 (pt) 2018-07-24
CN107849133B (zh) 2022-08-23
MX2017014136A (es) 2018-07-06
AU2016257929B2 (en) 2022-10-20
EA201792414A1 (ru) 2018-06-29
US10745481B2 (en) 2020-08-18
WO2016179285A1 (en) 2016-11-10
HRP20200721T1 (hr) 2020-10-02
HUE049866T2 (hu) 2020-11-30
MX2021014735A (es) 2022-01-18
DK3292150T3 (da) 2020-04-27
US20240076374A1 (en) 2024-03-07
US20160355587A1 (en) 2016-12-08
SG10201913767VA (en) 2020-03-30
HK1250036A1 (en) 2018-11-23
RS60222B1 (sr) 2020-06-30
KR20180010203A (ko) 2018-01-30
CN115340607A (zh) 2022-11-15
CA2984948A1 (en) 2016-11-10
PT3292150T (pt) 2020-06-01
CN107849133A (zh) 2018-03-27
MX388350B (es) 2025-03-19
US20200291113A1 (en) 2020-09-17
EP3708585A1 (en) 2020-09-16
JP2018520091A (ja) 2018-07-26
ES2796698T3 (es) 2020-11-30

Similar Documents

Publication Publication Date Title
US20240076374A1 (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
US20220306759A1 (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
US11472875B1 (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
US20240239904A1 (en) Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US10233244B2 (en) Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
US20180303952A1 (en) Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
US9517276B2 (en) Compositions and methods for conjugating activatable antibodies
EP4034171A1 (en) Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
HK40038123A (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
HK1250036B (en) Activatable anti-cd166 antibodies, and methods of use thereof
EA041958B1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения